Diagnosis and Management of Daptomycin-Induced Acute Eosinophilic Pneumonia: A Case Report.
Fawzy A ElbarbryKate FarthingShannon ArguelloPublished in: Innovations in pharmacy (2024)
Daptomycin is a cyclic lipopeptide antibiotic that is indicated for the treatment of complicated skin infections and bacteremia caused by gram positive organisms. Acute eosinophilic pneumonia (AEP) is a rare, but serious adverse effect of daptomycin and caused by accumulation of eosinophils in the lung tissues, and can lead to respiratory failure. Early diagnosis and management of this condition is crucial to avoid severe complications, including death. Herein, we report a case of an elderly man who presented with signs and symptoms of AEP within two weeks of initiation of daptomycin for the treatment of MRSA bacteremia. The patient showed significant clinical improvement and decline in eosinophils upon discontinuation of daptomycin and starting a 5-day steroid course. Acute eosinophilic pneumonia should be kept in mind as a possible, although rare, adverse effect of daptomycin. Early recognition can be established through typical symptoms, eosinophilia, and chest X-ray showing pulmonary infiltrate. Rapid discontinuation of daptomycin with/without steroid therapy and supportive care usually results in significant clinical recover.
Keyphrases
- respiratory failure
- methicillin resistant staphylococcus aureus
- extracorporeal membrane oxygenation
- mechanical ventilation
- staphylococcus aureus
- gram negative
- liver failure
- drug induced
- multidrug resistant
- gene expression
- acute respiratory distress syndrome
- pulmonary hypertension
- emergency department
- combination therapy
- chronic rhinosinusitis
- risk factors
- magnetic resonance
- quality improvement
- hepatitis b virus
- contrast enhanced
- chronic pain
- community acquired pneumonia
- soft tissue
- adverse drug